Drugs / JNJ-49122944
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02280018 | Nov → Dec 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-49122944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02280018 ↗ |
| Route | Intravenous | “administered as a 22.2 mL IV infusion over 45 minutes” NCT02280018 ↗ |